Introduction
Emerging data suggest that the natural history of mixed aortic valve disease (MAVD) differs from that of isolated aortic stenosis (AS) or isolated aortic regurgitation (AR). [1] [2] [3] [4] [5] Patients with MAVD tend to have a more rapid progression of symptoms requiring aortic valve replacement (AVR) than do patients with isolated AS or AR of similar severity. 1 Mixed aortic valve disease creates a combination of pressure and volume load on the left ventricle, resulting in an increase in left ventricular (LV) mass and diastolic filling pressure. A recent study from our group reported that LV concentric hypertrophy was a risk factor for adverse events in this population. 1 Although LV concentric hypertrophy is associated with reduced LV relaxation and compliance, [6] [7] [8] the role of diastolic function indices in MAVD is unknown.
The purpose of the study was to determine the role of baseline diastolic function indices in predicting the occurrence of AVR or cardiac death, and also in predicting the risk of future cardiovascular adverse events (CAEs) after AVR.
. 
Methods Study design and patient selection
This is a retrospective review of all asymptomatic patients [New York Heart Association (NYHA) class 1, age > 18 years] with moderate MAVD followed up at Mayo Clinic, Rochester, from 1 January 2004, to 31 December 2013. The patients were identified from the electronic health records database by using a free query tool (Advanced Cohort Explorer). The Mayo Clinic Institutional Review Board approved this study and waived written informed consent for those who provided research authorization. Cardiovascular outcomes in this cohort have been previously described. 1 The criteria for including patients in the study were moderate MAVD (combination of moderate AS and moderate AR), normal left ventricular systolic function [LV ejection fraction (EF) > _ 50%], assessment of diastolic function (at least three of the following indices: a tissue Doppler early velocity (e 0 ) of the mitral annulus, mitral inflow early velocity (E), tricuspid regurgitation velocity, and left atrial volume index), and at least 2 years of clinical and echocardiographic follow-up. Patients with the following conditions were excluded: prior endocarditis, prior aortic valve intervention, radiation-induced valvular heart disease, and coexistent valvular heart disease defined as moderate or greater stenosis or regurgitation of the mitral, tricuspid, or pulmonary valves. The data of the patient enrolled in the current study have been previously published.
1,2
Data collection, follow-up and endpoints Clinical, echocardiographic, and surgical data were abstracted from the health records. Our definitions for clinical data were the same as those used in previous studies.
1,2 The primary endpoint was AVR or cardiac death while the secondary endpoint was the occurrence of CAE after AVR.
For the purpose of this study, a CAE was defined as ischaemic stroke, heart failure hospitalization, severe LV dysfunction, or cardiac death. Stroke was defined as ischaemic or haemorrhagic cerebrovascular events confirmed by brain computed tomography scans or magnetic resonance imaging scans. Heart failure hospitalization was defined as a hospitalization for worsening heart failure symptoms requiring intravenous diuretics. Severe LV dysfunction was defined as LVEF less than 35%. Cardiac death was defined as death directly related to a cardiac cause, such as congestive heart failure, myocardial infarction, or sudden death. Only one event was counted per patient, and in the patients with more than one CAE, the earliest event was considered the CAE for that patient.
Echocardiography
According to the guidelines, [9] [10] [11] [12] we defined moderate AS as a peak velocity of 3.0 to 3.9 m/s and a valve area of 1.1 to 1.5 cm 2 . Moderate AR was defined as a combination of at least two of the following: vena contracta, 0.3 to 0.6 cm; regurgitant volume, 30 to 59 mL; effective regurgitant orifice area, 0.10 to 0.29 cm 2 ; and angiographic grade 2þ regurgitation. The left ventricular mass index (LVMI), relative wall thickness (RWT), and EF were calculated using 2D echocardiography; and the left atrial volume index was calculated by area-length or biplane methods. 13, 14 Relative wall thickness is measure of concentric LV hypertrophy or remodelling and was calculated using the formula: (2 Â posterior wall thickness)/left ventricular end diastolic diameter. 13, 14 The diastolic function indices analysed in this study were e 0 of the mitral annulus, E, ratio of E/e 0 , tricuspid regurgitation velocity, left atrial volume index, and pulmonary vein pulse wave Doppler velocity. For tissue Doppler velocities, with collected and analysed both lateral and septal e 0 velocities. We then calculated average e 0 velocity as the mean of septal and lateral e 0 velocities.
Statistical analysis
All statistical analyses were performed using JMP version 11.0 software (SAS Institute Inc). Categorical variables were expressed as percentages, and continuous variables were expressed as mean (±standard deviation). All diastolic function indices of the patients in sinus rhythm were fitted into a univariable model to identify the predictors of cardiac death or AVR. These indices were dichotomized using the cut points stipulated in the American Society of Echocardiography guidelines. 15 The indices that reached statistical significance (P < 0.05) were then incorporated into a previously described multivariable Cox model comprising clinical and echocardiographic variables using forward selection. 1 The strength of association for each variable was expressed as hazard ratio (HR) and 95% CI. The freedom from cardiac death and AVR were assessed using the Kaplan-Meier method and compared using the log-rank test. The time of first echocardiographic diagnosis of moderate MAVD was considered as time zero while the last clinic visit or patient's clinical correspondence was considered as the end of the follow-up period. The degree of LV reverse remodelling was assessed and compared using two-way ANOVA.
For secondary end point analysis, we reviewed data from all patients who had an AVR and had at least 1 year of follow-up. The freedom from CAE (ischaemic stroke, heart failure hospitalization, severe LV dysfunction, or cardiac death) was assessed using the Kaplan-Meier method and compared using the log-rank test. The time of hospital dismissal after AVR was considered as the time zero for secondary end point analysis. P values <0.05 were considered significant.
Results
There were 214 patients who met the inclusion criteria for the study and these patients were followed for 6.3 ± 2.1 years. The mean age of the study group was 61 ± 8 years. Of the patients, 146 (68%) were men. All patients had clinical and echocardiographic follow-up every 12 to 18 months or sooner if they developed symptoms. Table 1 shows the baseline clinical characteristics of the cohort, and Figure 1 in table for regurgitation velocity (n = 181), left atrial volume index (n = 187), and pulmonary vein Doppler velocity (n = 143). Table 2 shows echocardiographic data at baseline and before AVR.
AVR and cardiac death
A total of 162 patients (76%) underwent AVR within 4.2 ± 2.5 years. The indication for AVR was the development of symptoms (angina, NYHA class III/IV dyspnea, exertional syncope, or pre-syncope) in 156 patients (96%) and an abnormal stress test in the setting of severe AS in 6 patients (4%). From the beginning of the study period to the time of AVR, 120 patients (74%) progressed to severe AS; 23 (14%) progressed to severe AR; and 19 (12%) had no progression in the severity of aortic valve disease. A mechanical prosthesis was implanted in 84 (52%) patients, and a bioprosthetic valve was implanted in 78 (48%) patients. Concomitant procedures performed at the time of AVR were aorta replacement (24 patients [15%]) and coronary artery bypass grafting (31 patients [19%] ). One patient (0.6%) died in the perioperative period: a 75-year-old man with a mechanical prosthesis who had a massive stroke 21 days after AVR.
Of the 214 patients, there were 11 cardiac deaths (5%), including the perioperative death; of these, 6 occurred in the non-AVR group. The primary endpoint of cardiac death or AVR was reached in 168 patients (79%). Tables 3 and 4 show the univariable and multivariable models for the 185 patients in sinus rhythm. (5) 14 (3) Mean E/e 
Cardiovascular adverse events
Of the 185 patients in sinus rhythm, 139 had at least 1 year of postoperative clinical and echocardiographic follow-up data available. Table 5 shows the clinical characteristics of these patients at the time of hospital discharge. On the basis of data from the baseline echocardiograms, 50 of these 139 patients were in the high-risk group (RWT > 0.42 or average E/e 0 > 14), and 89 patients were in the lowrisk group (RWT < _ 0.42 and average E/e 0 < _ 14).
A total of 43 CAEs occurred in 34 patients (25%) during 3.6 ± 1.7 years of post-operative follow-up. These CAEs were stroke (n = 13), heart failure hospitalization (n = 19), severe LV systolic dysfunction (n = 7), and cardiac death (n = 4). The freedom from CAE was significantly lower in the high-risk group (79% [95% CI 74-83%] at 3 years and 64% [95% CI 59-68%] at 5 years) than in the low-risk group (94% [95% CI 89-98%] at 3 years; and 83% [95% CI 78-89%] at 5 years) (P = 0.03) ( Figure 2B ).
LV reverse remodelling
Of the 139 patients with post-operative follow-up, 135 had a comprehensive assessment by echocardiography with diastolic function 1 year after AVR. The interval from AVR to echocardiography (12 ± 2 vs. 13 ± 2 months; P = 0.43) and the prosthetic gradient (18 ± 4 vs. 17 ± 6 mmHg; P = 0.41) were similar in the high-and lowrisk groups. LVMI decreased significantly in the high-risk group 
Discussion
The current study showed that the presence of concentric LV hypertrophy and/or increased LV filling pressure were risk factors for rapid symptomatic deterioration and need for AVR in patients with moderate MAVD. These patients also remain at a higher risk for CAE even after AVR.
Pre-operative risk stratification
Of all the indices of diastolic function analysed in this study, the average E/e 0 > 14 was an independent risk factor for cardiac death or AVR. The presence of concentric LV hypertrophy (RWT > 0.42) and/or increased LV filling pressure (E/e 0 > 14) was characteristic of a high-risk patient subset who had a more rapid progression of symptoms requiring AVR. Peak aortic velocity is the strongest predictor of symptomatic deterioration in patients with isolated AS. [16] [17] [18] Stewart et al. 19 studied the role of diastolic function indices in 183 asymptomatic patients with moderate to severe AS (peak velocity > 3 m/s) and an LVEF of 50% or more. The study showed an association between E/e 0 and symptomatic deterioration. However, only peak aortic velocity was predictive of symptoms on multivariable analysis, and there was no significant association between diastolic function indices and symptomatic deterioration in that cohort after adjustment for peak aortic velocity. Left ventricular dimension and EF are prognostic for adverse outcome in patients with isolated AR. 20, 21 In a cohort of 41 patients with chronic, severe AR and LV dysfunction, Cayli et al. 22 analysed the role of diastolic function indices in predicting outcomes after AVR. The patients were categorized into three groups on the basis of severity of diastolic dysfunction. The patients with impaired relaxation showed the greatest improvement in EF, while those with a restrictive filling pattern showed a decline in EF after AVR. The role of assessing diastolic function in MAVD is unknown, and the current study shows that diastolic function indices may help refine risk stratification in this population. Mixed aortic valve disease is characterized by a combination of pressure and volume load, resulting in pressure-related concentric hypertrophy due to AS and chamber dilatation due to AR. As a result, the operative compliance of the LV decreases, causing a greater increase in diastolic pressure per unit of volume increase in the LV during the diastolic filling period. 23, 24 We postulate that symptomatic deterioration in patients with MAVD is driven in part by the severity of diastolic dysfunction. In support of this argument, 9% of the cohort (19 patients) required AVR for symptomatic deterioration even in the absence of progression in the severity of aortic valve disease. All 19 patients had an RWT > 0.42 and average E/e 0 > 14. Perhaps, the risk factors proposed in the current study indicate a patient subset with the most unfavourable haemodynamics, operating at the rightwards extreme of the compliance curve.
Post-operative risk stratification
The surgical mortality after AVR was less than 1% in this selected cohort of patients with MAVD and normal EF. However, one-fourth of the patients experienced CAEs, such as stroke, heart failure hospitalization, severe LV dysfunction, and cardiac death within a mean follow-up period of 4 years. CAEs were more common in patients with RWT > 0.42 and/or average E/e 0 >14.
The valvular heart disease guidelines recommend AVR before the onset of LV systolic dysfunction. 9, 10 This timing is critical to avoid the cardiovascular morbidities that can occur once LV dysfunction ensues. These recommendations are based on data derived from patients with isolated AS or AR. 16, 17, 21, 25, 26 A major pitfall of determining the timing of AVR in MAVD using the criteria for isolated lesions is the inherent assumption that the haemodynamic impact of combined pressure and volume load on the LV is not remarkably different from that of isolated pressure or volume load.
In this study, we presumed that all of our patients had normal preoperative LV systolic function on the basis of normal EF, which is a load-dependent index of LV contractility. Perhaps some of the patients already had decreased LV contractility before AVR, which was masked by the complex loading conditions present in MAVD. Villari et al. 24 performed invasive haemodynamic studies of 58 patients with isolated AS and AR using simultaneous LV biplane cineangiography and LV high-fidelity pressure measurements. They showed that most of their patients had abnormal indices of diastolic function despite preserved systolic contractile function. Because diastolic dysfunction precedes systolic dysfunction, diastolic function indices may have a substantial role in the early identification of high-risk patients, as shown in the current study.
LV reverse remodelling and risk modification
The patients with concentric LV hypertrophy and elevated LV filling pressure before AVR had less LV reverse remodelling, as shown by less robust regression of hypertrophy 1 year after AVR. In addition, increased LV filling pressure (average E/e 0 > 14) persisted after AVR in more than two-thirds of these patients. Beach et al. 27 studied the pattern of LV reverse remodelling after AVR in 4264 patients with isolated AS. Regression of LV hypertrophy occurred within the first 2 years after AVR, but LVMI never normalized. Severe LV hypertrophy and left atrial dilatation pre-operatively were associated with less regression of LV hypertrophy after AVR and reduced long-term survival in that study. 27 We observed a very similar pattern in our cohort. The patients with pre-operative concentric hypertrophy and increased LV filling pressure had less LV reverse remodelling after AVR and more CAEs. It is important to note that the Beach et al.
27
study included patients with different severities of LV systolic dysfunction, and this could have contributed to the observed results. In contrast, our patients had normal EFs before AVR, suggesting that reliance on this load-dependent index of systolic function may not yield the best prediction of post-operative risk. Concentric LV hypertrophy is an adaptive mechanism characterized by parallel replication of new sarcomeres intended to increase wall thickness and normalize wall stress. 28, 29 This adaptive mechanism becomes maladaptive beyond a certain point, resulting in a deterioration of cardiac function despite normal wall stress. 30 The holy grail of pre-operative risk stratification will be to identify and intervene at that cut point, in order to prevent the downstream effects of LV maladaptation. The current study, with all its inherent limitations, does not provide that cut-point but rather suggests a new tool that may help identify high-risk patients. What to do with these high-risk patients remains unclear. An overly simplistic approach would be to shorten the duration of combined pressure and volume overload by performing early surgical intervention, the timing of which may be guided by RWT and E/e 0 . This has to be balanced against the risk of surgery, increased chances of future reoperations, and complications associated with prosthetic valves. Further studies are required to address these unanswered questions.
Limitations
This is retrospective, single-centre study. Because of the study's retrospective nature, we were unable to determine how long the patients were symptomatic before AVR. In addition, we relied on the indications for AVR as documented in the clinic notes. Another major 
